Form 4: HilleVax Director Aditya Kohli Sells Shares Under 10b5-1 Trading Plan

Director Aditya Kohli of HilleVax, Inc. executed sales of common stock between March 6 and March 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Aditya Kohli, a director of HilleVax, Inc., sold shares of common stock between March 6 and March 8, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on October 12, 2023.
• On March 6, 2024, 6,000 shares were sold at a weighted average price of $18.9501, with individual prices ranging from $18.58 to $19.51.
• On March 7, 2024, another 6,000 shares were sold at a weighted average price of $18.3688, with individual prices ranging from $17.91 to $18.92.
• On March 8, 2024, a further 6,000 shares were sold at a weighted average price of $18.6598, with individual prices ranging from $18.37 to $18.97.
• Following these transactions, Kohli directly owns 825,776 shares of HilleVax, Inc.
• The sales were reported on a Form 4 filing with the Securities and Exchange Commission.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The sales are part of a pre-planned trading plan, so they don't necessarily indicate a negative outlook, but large insider sales can sometimes create uncertainty.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the sales are under a 10b5-1 plan, large insider sales can sometimes create negative market sentiment.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan is a standard practice to avoid accusations of trading on non-public information. The market will likely assess the sales in the context of HilleVax's overall performance and future prospects.

Comparison to Industry Standards

• Comparing HilleVax to similar biotech companies, insider selling is a common practice, especially after periods of stock appreciation.
• Companies like Moderna and BioNTech have seen similar patterns of insider selling after significant stock price increases.
• The key is whether the selling is part of a pre-planned strategy or indicative of a lack of confidence in the company's future.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan should mitigate concerns.
• Employees may be indirectly affected by any stock price fluctuations resulting from the sales.

Key Dates